The Appropriate Anticoagulation Duration for Chronic Obstructive Pulmonary Disease With Pulmonary Thromboembolism

Chinese Academy of Medical Sciences, Fuwai Hospital

Status: Unknown

Conditions: PTE - Pulmonary Thromboembolism; COPD Exacerbation

Treatments: Drug: Warfarin

Study type: Interventional

Funder types: Other

Identifiers

NCT03185845

2016YFC1304402B

Details and patient eligibility

About

Anticoagulation is the most important treatment for pulmonary thromboembolism (PTE). The thromboembolism risk is especially high in patients with chronic obstructive pulmonary disease (COPD) exacerbations. However, there's no agreement on the most appropriate duration of anticoagulation in COPD with PTE to balance the risk of recurrence of thrombosis and bleeding. This randomized, controlled trial aims to evaluate the risk and benefit of prolonged anticoagulation compared with the regular 3-month anticoagulation in COPD with PTE.

Enrollment: 392 estimated patients

Sex: All

Ages: 40+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Hospitalized patients due to chronic obstructive pulmonary disease exacerbation and diagnosed as newly developed pulmonary thromboembolism
• Regular anticoagulation for 3 months and got CT pulmonary angiography

Exclusion criteria

• Patients with major bleeding during prior anticoagulation
• Patients need long term anticoagulation to treat other diseases
• Patients unwilling to receive prolonged anticoagulation

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

392 participants in 2 patient groups

Prolonged anticoagulation

Experimental group

Description:

3 months longer anticoagulation after regular treatment

Treatment:

Drug: Warfarin

Regular anticoagulation

No Intervention group

Description:

stop anticoagulation after regular treatment